These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 7771262)

  • 21. Gliclazide: metabolic and vascular effects--a perspective.
    Alberti KG; Johnson AB; Taylor R
    Metabolism; 1992 May; 41(5 Suppl 1):40-5. PubMed ID: 1574015
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Glibenclamide vs gliclazide in reducing oxidative stress in patients of noninsulin dependent diabetes mellitus--a double blind randomized study.
    Chugh SN; Dhawan R; Kishore K; Sharma A; Chugh K
    J Assoc Physicians India; 2001 Aug; 49():803-7. PubMed ID: 11837468
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group.
    Lancet; 1998 Sep; 352(9131):837-53. PubMed ID: 9742976
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of diabetic control in type 2 (non-insulin dependent) diabetic patients treated with different sulphonylureas.
    Harrower AD
    Curr Med Res Opin; 1985; 9(10):676-80. PubMed ID: 3935376
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The effect of sulphonylurea therapy on skeletal muscle glycogen synthase activity and insulin secretion in newly presenting type 2 (non-insulin-dependent) diabetic patients.
    Johnson AB; Argyraki M; Thow JC; Jones IR; Broughton D; Miller M; Taylor R
    Diabet Med; 1991 Apr; 8(3):243-53. PubMed ID: 1828740
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The mode of action and clinical pharmacology of gliclazide: a review.
    Campbell DB; Lavielle R; Nathan C
    Diabetes Res Clin Pract; 1991; 14 Suppl 2():S21-36. PubMed ID: 1794262
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antioxidant and vascular effects of gliclazide in type 2 diabetic rats fed high-fat diet.
    Sena CM; Louro T; Matafome P; Nunes E; Monteiro P; Seiça R
    Physiol Res; 2009; 58(2):203-209. PubMed ID: 18380531
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Gliclazide. An update of its pharmacological properties and therapeutic efficacy in non-insulin-dependent diabetes mellitus.
    Palmer KJ; Brogden RN
    Drugs; 1993 Jul; 46(1):92-125. PubMed ID: 7691511
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy of gliclazide in comparison with other sulphonylureas in the treatment of NIDDM.
    Harrower AD
    Diabetes Res Clin Pract; 1991; 14 Suppl 2():S65-7. PubMed ID: 1794268
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of gliclazide and glibenclamide treatment in non-insulin-dependent diabetes.
    Baba S; Nakagawa S; Takebe K; Goto Y; Maezawa H; Takeda R; Sakamoto N; Fukui I
    Tohoku J Exp Med; 1983 Dec; 141 Suppl():693-706. PubMed ID: 6440313
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sulfonylureas and platelet function.
    Klaff LJ; Kernoff L; Vinik AI; Jackson WP; Jacobs P
    Am J Med; 1981 Mar; 70(3):627-30. PubMed ID: 6782875
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mortality outcomes of different sulphonylurea drugs: the results of a 14-year cohort study of type 2 diabetic patients.
    Bo S; Castiglione A; Ghigo E; Gentile L; Durazzo M; Cavallo-Perin P; Ciccone G
    Eur J Endocrinol; 2013 Jul; 169(1):117-26. PubMed ID: 23660643
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Catalase/superoxide dismutase (SOD) and catalase/paraoxonase (PON) ratios may implicate poor glycemic control.
    Sözmen EY; Sözmen B; Delen Y; Onat T
    Arch Med Res; 2001; 32(4):283-7. PubMed ID: 11440784
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Preventive and therapeutic effects of gliclazide on diabetic retinopathy: comparison with glibenclamide treatment.
    Minami N; Ikeda Y; Abe M
    Tohoku J Exp Med; 1983 Dec; 141 Suppl():707-11. PubMed ID: 6440314
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Normalization of plasma lipid peroxides, monocyte adhesion, and tumor necrosis factor-alpha production in NIDDM patients after gliclazide treatment.
    Desfaits AC; Serri O; Renier G
    Diabetes Care; 1998 Apr; 21(4):487-93. PubMed ID: 9571329
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Metformin or gliclazide, rather than glibenclamide, attenuate progression of carotid intima-media thickness in subjects with type 2 diabetes.
    Katakami N; Yamasaki Y; Hayaishi-Okano R; Ohtoshi K; Kaneto H; Matsuhisa M; Kosugi K; Hori M
    Diabetologia; 2004 Nov; 47(11):1906-13. PubMed ID: 15565373
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of glycaemic control, metformin and gliclazide on platelet density and aggregability in recently diagnosed type 2 (non-insulin-dependent) diabetic patients.
    Collier A; Watson HH; Patrick AW; Ludlam CA; Clarke BF
    Diabete Metab; 1989; 15(6):420-5. PubMed ID: 2534084
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Gliclazide treatment lowers serum ICAM-1 levels in poorly controlled type 2 diabetic patients.
    Papanas N; Tziakas D; Chalikias G; Floros D; Trypsianis G; Papadopoulou E; Kortsaris A; Symeonidis G; Souliou E; Maltezos E; Hatseras D
    Diabetes Metab; 2006 Sep; 32(4):344-9. PubMed ID: 16977262
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hemobiological properties of gliclazide.
    Ziegler O; Drouin P
    J Diabetes Complications; 1994; 8(4):235-9. PubMed ID: 7833500
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Lack of effect of gliclazide on early diabetic nephropathy and retinopathy: a two-year controlled study.
    Jerums G; Murray RM; Seeman E; Cooper ME; Edgley S; Marwick K; Larkins RG; Martin TJ
    Diabetes Res Clin Pract; 1987; 3(2):71-80. PubMed ID: 3552537
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.